Alnylam Pharmaceuticals : 2024 REPORT
ALNY
Published on 05/20/2025 at 09:00
Introduction
Introduction
Corporate Responsibility Report 2024 Patients
Science
Employees
Communities
Planet
Governance
Data
Table of Contents
03 | CEO Message 05 | About Alnylam 07 | 2024 Highlights
08 | Corporate Responsibility at Alnylam 14 | Patients
25 | Science
Catalina, patient (Spain)
2
38 | Employees
53 | Communities
63 | Planet
73 | Governance
85 | Data Summary
On the cover, left: Tsuyoshi, patient and his wife Rika (Japan)
Introduction
CEO Letter
In our quest to realize the tremendous potential of RNAi therapeutics, 2024 was a pivotal year. We emerged as a top-tier biotechnology company, with a flagship franchise, a spring-loaded pipeline, a strong financial foundation, and a culture alive with purpose and innovation. Before us lies a profound opportunity: to reshape the future of medicine and impact the lives of millions of patients.
At this transformational moment, we remain steadfast in our belief that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all.
In our 2024 Corporate Responsibility Report, Alnylam's 'Challenge Accepted' ethos is showcased in the unwavering efforts of teams across the business to increase the value we deliver to society.
This year was highlighted by the overwhelmingly positive data from the landmark HELIOS-B study of vutrisiran for patients with ATTR amyloidosis with cardiomyopathy. The study demonstrated
a substantial impact in reducing mortality and improving quality
of life, and we are thrilled with what these results mean for patients, physicians, families, and caregivers. We made equally strong progress in advancing potentially transformative medicines to treat a broad range of both rare and prevalent diseases.
At Alnylam, we believe we are responsible for ensuring the patients who can benefit from our medicines have access to them. No patient should have to wait for hope. Our Patient Access Philosophy continues to guide us, holding us accountable for ensuring that access and outcomes align with the value our therapies bring to patients.
3
Corporate Responsibility Report 2024
Patients
Science
Employees
Communities
Planet
Governance
Data
Introduction
Introduction
Patients
Science
Employees
Communities
Planet
Governance
Data
Our people are the driving force behind Alnylam's RNAi leadership. Grounded by our Core Values, we continue to be a beacon for talent through a focus on great science, a diverse and inclusive culture, and upholding the highest professional and ethical standards.
While we are honored to receive many 'Best Places to Work' awards, we are most proud of the high marks from our own people. In our annual culture survey, 80% of employees recommend Alnylam
as a great place to work, and 88% feel that they are accepted and treated fairly by the company and their peers. In this report, you will see stories of our growing Employee Resource Networks (ERNs), expansion of benefit programs, and efforts to recruit and develop top performers that underpin these results.
The passion to improve human health is the driver of our community impact work. Our signature program, Alnylam Challengers, seeks to improve health outcomes by rallying behind bold leaders and organizations increasing access to personalized care and support services for under-resourced communities. In 2024, our employees once again dedicated time and funds to help others, including volunteering across 14 countries during our 4th annual Community Service Week and donating to humanitarian relief organizations during crises and natural disasters.
We continuously seek to minimize our impact on the environment and work to address the growing threat of climate change. Our increasing ability to gather robust data and track energy and natural resource usage enables us to activate new strategies to protect the planet and respond to regulatory requirements. This year we achieved a significant milestone in efforts to manage our carbon footprint with third-party verification of our Scope 1, 2, and 3 greenhouse gas (GHG) emissions. In addition, our Alewife and Norton manufacturing facilities are now 100% powered by renewable energy.
The moment in front of us is more promising than any before and the opportunities more extraordinary. We are just getting started and believe that the best is yet to come.
Sincerely,
Yvonne Greenstreet, MD, MBA
Chief Executive Officer
Together, we have been on a 23-year quest to realize the
extraordinary promise of RNAi.
This year was one of great achievements in that journey."
4
Corporate Responsibility Report 2024
Introduction
Introduction
Corporate Responsibility Report 2024
Introduction
Patients
Science
Employees
Communities
Planet
Governance
Data
About Alnylam
Alnylam's pioneering science has yielded critical breakthroughs and innovations that have made RNAi therapeutics a reality. This class of medicines is fundamentally impacting the lives of patients around the world.
5
Disclaimer
Alnylam Pharmaceuticals Inc. published this content on May 20, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 20, 2025 at 12:59 UTC.